P5, line 23, review this sentence -Do you mean "consults initiated in communities" or are you talking about asynchronous interpretation of test results -or both?
P5, lines 47-57: what are the classification levels of hearing loss for these two populations -are they comparable? Variously 25 dB, 30 dB and 40 dB are often used as cut-offs for hearing loss and clearly prevalence will be influenced depending on the level used so just make that clear here.
Methods:
Page 10, line 30: Agree with the stakeholders. Also wonder whether all children could receive the expedited telehealth referral and compare this to an estimated time for primary care referral. May not be possible, but in some jurisdictions with centralised referral services you can get a very accurate prediction of how long you will wait for a specialist referral to audiologist, paediatrician, ENT etc. Worth considering if possible/practicable in this study.
Page 10, line 52 -generate a referral to whom? Family physician, ENT, audiologist?
Page 11, Line 18: Please describe what is meant by "screening tympanometry". Will a different protocol/device be used as opposed to routine tympanometry?
Page 11, Line 19: Rephrase, "her" does not seem to be the most appropriate when describing New Zealand. E.g. "Maori and Pacific Islander populations of New Zealand have a similarly…" Page 11, Line 49: I agree with the referral criteria, including single threshold >30dB referral. However, perhaps only need to conduct bone-conduction if hearing loss reaches threshold for referral, otherwise you are over-testing children unless you plan to examine air-bone gaps in children with normal hearing.
Page 11, Line 54: Have you considered how you will deal with children who have grommets (aka ventilation tubes)? They will have a Type B tymp but will not likely require a re-referral.
GENERAL COMMENTS
Dr. Emmett at al have a developed a protocol involving a RCT design to study a telemedicine model of school hearing screening in rural Alaska. I applaud their efforts as this is a needed area of research for a vulnerable population. The study design is sound and the outcome measure are appropriate. They have take care to include community stakeholders into the study design and protocol. I only have a couple comments questions regarding the protocol: 1. Might it be possible to include any of the preliminary work that guided the protocol development. 2. Were other study designs considered? The intervention/test condition is called the expedited telemedicine protocol. The name of this implies that children will receive better or more efficient care. There could be some communities that find out that they are not getting the "better" version of the intervention. This could cause some conflict. Could you consider a wait-list control or a step-wedge trial design since that would allow all communities to receive the intervention eventually, but just not a the exact same time. It would also allow you to receive some standard of care condition data on all of the communities as well.
Again, this work is very important and will likely make a significant impact on research involving school screening in rural communities.
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GENERAL COMMENTS p8 li50-55: Understanding this sentence is hard work. Could it be revised, using simpler language? p12: lie 39: "Including all types of providers", might be better as: " The inclusion of all types of providers" p14 li 24: Is there a precedent to justify the assumption that there might be expected to be 80% recruitment. This is very high! P14 li 31: What is the trial vulnerability to specific communities not wishing to participate? How are the investigators mitigating this risk? For instance, one possible outcome of the consultation process is that (a) key opinion leader(s) in a community advises to others that they would be best not to participate. this could influence opinion in other communities. The knock-on effects would be quite devastating. p15: li 20: Has data linkage been agreed to? this is often a critical impasse for studies across Governmental bodies. p15, Li31-2: How will the risk that students will forget that they have been given paper versions of the trial questions be managed? Many children, especially teenagers, simply forget that they have been given material to take home to parents! p18, li 16: It would be good to specify what defines management, especially given that it will be heterogenous and may be interpreted differently by different trial staff. decisions will need to be made on some difficult questions here: is "watchful waiting" active management? the management of a child too young for myringoplasty might simply be to wait. This is a well-reasoned and generally well executed study protocol. It addresses an important topic and will be one the most rigorous assessments of telehealth diagnosis within this context. The study will likely have significant, positive implications for the care of participants in the study and the results will help inform approaches to telehealth in other jurisdictions.
General comments:
Consider incorporating an additional analysis of hearing data as a continuous outcome. Criteria for hearing loss as a dichotomous outcome are variable depending of which jurisdictional guidelines you follow. Additionally, pure-tone averages can be deceiving, and children with substantial, but frequency-specific hearing losses can be classed as "normal". Incorporating hearing as a continuous variable will improve the generalisability of the study and make it easier to quantify more nuanced improvements in hearing level.
Thank you for your suggestion. We agree that there is more statistical power with continuous outcomes and that frequency-specific losses are not captured by a pure-tone average. In this trial, frequency-specific hearing losses in the audiometric assessment will generate a referral per trial protocol. The distribution of reasons for referral generated by audiometric assessment, including frequency-specific losses, will be documented as part of the descriptive statistics after screening in year 1 and year 2. We will also describe the distributions referral conditions from each of the screening protocols. Similarly, quantitative changes in these individual referral categories will be evaluated to gain insights on change, or lack thereof, in hearing loss prevalence over time. We agree that these are all important mechanistic outcomes to help us better understand the main hearing loss outcome we selected. We focus on change in prevalence of hearing loss by WHO criteria of PTA>25 (0.5, 1, 2, 4 Hz), which we feel is most meaningful from a public health perspective and is easiest to communicate with the participating communities and various stakeholders, including policymakers.
Throughout there are many mentions of referral but it is not always clear to whom a child would be being referred. Although there are figures, for clarity this could also be mentioned in the text.
Thank you for this comment. Explanatory text has been added to the referral sections on pages 11-12.
Specific comments:
Abstract: Consider mentioning specific recruitment target (e.g. 1500 participants)
The recruitment target has been added to the abstract (p3).
Introduction:
The use of "treatable hearing loss" is somewhat confusing -you do mention chronic otitis media, but many would argue that both conductive and sensorineural hearing loss are treatable depending on the context (i.e. hearing aids as 'treatment').
"Treatable" has been removed (p3 and 5).
We have clarified that consults are initiated in communities and read remotely in an asynchronous fashion (p5).
We have clarified that the definition of hearing loss used in both population was PTA>25dB, averaged over 500, 1000, and 2000 Hz (p5).
Methods:
We too agree with our stakeholders, and this is why all children receive the current school screening protocol, mHealth protocol, and full audiometric assessment, as well as why we selected cluster randomization by community to assess referral pathways. We appreciate your suggestion of comparing an estimated time to primary care referral, but unfortunately there is no centralized referral service in rural Alaska to facilitate this comparison.
We have added a line indicating that referral pathways are described in the following section (p9).
We have deleted the word "screening" (p10).
Page 11, Line 19: Rephrase, "her" does not seem to be the most appropriate when describing New Zealand. E.g. "Maori and Pacific Islander populations of New Zealand have a similarly…" "Her" has been deleted (p10).
Page 11, Line 49: I agree with the referral criteria, including single threshold >30dB referral. However, perhaps only need to conduct bone-conduction if hearing loss reaches threshold for referral, otherwise you are over-testing children unless you plan to examine air-bone gaps in children with normal hearing.
Thank you for this suggestion. We are indeed only performing bone conduction on children with hearing loss, so we have clarified the language to indicate this (p10-11).
Yes, we have discussed this extensively as a team, including with our lead ENT stakeholder, who leads the department that provides surgical ENT care for the Alaska Native population statewide. We recognize that children with tympanostomy tubes will generate a referral based on a type B tymp. These children require monitoring every 6-months, as the recurrent nature of middle ear disease in Alaska often necessitates multiple sets of tympanostomy tubes and/or tympanoplasties for residual perforations. Monitoring is currently performed through telemedicine consultation using digital otoscopic images and tympanometry, similar to the design of our expedited telemedicine intervention. These children can be lost to follow up, so the stakeholder team is comfortable with re-referral to confirm that they are indeed receiving the follow-up care required and feel this is a worthwhile compromise in order to better identify children with previously undiagnosed middle ear disease. The alternative to avoid referral of children with tympanostomy tubes would be to include otoscopy in the screening protocol. However, we do not feel this is appropriate in a screening protocol performed by lay persons.
Page 13, Line 43: Consider also including time-to-treatment in addition to time-to-diagnosis.
Thank you for this suggestion. We will have the capacity to evaluate complete treatment pathways for the most common diagnoses in secondary analyses and plan to do so after trial outcomes have been reported. Because of the heterogenous nature of management of hearing loss and ear disease on a population level, we are focusing specifically on time to diagnosis for the trial itself, as this will provide a proxy for time to entry to the healthcare system. Our main goal is to reduce the number of children lost to follow up after school screening and to reduce time to entry to the healthcare system. Page 14, Line 28: Yes, but you are using the WHO criteria for hearing loss (all ages), as opposed to disabling hearing loss in children, which is >30 dB 4FA. Might be worth just making that clearer as your prevalence will be higher than studies using the WHO disabling childhood hearing loss criteriaor consider changing your criteria to be >30 dB 4FA.
We have added a sentence clarifying why we selected the WHO criteria of PTA >25dB instead of the criteria of disabling childhood hearing loss (p13).
References
Page 25, Line 14: 'Hear' is not italicised in 'Ear Hear'
This has been corrected (p24). Dr. Emmett at al have a developed a protocol involving a RCT design to study a telemedicine model of school hearing screening in rural Alaska. I applaud their efforts as this is a needed area of research for a vulnerable population. The study design is sound and the outcome measure are appropriate. They have take care to include community stakeholders into the study design and protocol. I only have a couple comments questions regarding the protocol: 1. Might it be possible to include any of the preliminary work that guided the protocol development.
Thank you for your review and supportive comments. We have discussed the feasibility of including qualitative data that informed refinement of the protocol but ultimately felt that this information is beyond the scope of a protocol paper that is already quite dense. We are working on writing this up separately as a process paper that explains community input into protocol refinement.
2.
Were other study designs considered? The intervention/test condition is called the expedited telemedicine protocol. The name of this implies that children will receive better or more efficient care. There could be some communities that find out that they are not getting the "better" version of the intervention. This could cause some conflict. Could you consider a wait-list control or a step-wedge trial design since that would allow all communities to receive the intervention eventually, but just not a the exact same time. It would also allow you to receive some standard of care condition data on all of the communities as well.
We too are sensitive to the concern that all children receive benefit from participating in the study, which is why all children receive additional screening in the form of the mHealth screening protocol and full audiometric evaluation regardless of randomization. This suggestion came directly from our stakeholder team. Additionally, randomization did not occur until all communities had parental written consents for at least 50% of eligible children, and the randomized referral assignment of a community was kept confidential within the study team until hearing screening day in that community. Lastly, we do not use the language expedited telemedicine or primary care when discussing the study with families. Instead, we describe directly what may happen -that their child will either receive a letter home if they refer the hearing screen or will be taken directly to clinic for an appointment. Each of these factors should help to prevent conflict over randomization assignments.
We did consider other study designs when planning this trial, including a step-wedge design. Ultimately, we opted for a cluster randomized design for several reasons. The current primary care referral process has never been evaluated, so our stakeholders felt it was important to assess the current process when comparing to a telemedicine referral process. Secondly, while telemedicine has been used for clinical care for many years in Alaska, it has never been applied for prevention. The telemedicine referral process being tested in this trial requires schools and clinics to work together to facilitate referrals (something that has never been required before), and so we don't feel we can make the assumption that this system will work better than the current referral process based on preliminary (clinical) data alone. The more effective referral process will be implemented in all communities after the trial has confirmed effectiveness. There are only 15 clusters in the study because that is how many communities there are in the Norton Sound region. The brief time-frame of a school-based RCT over 2 academic years, with screening happening only once annually in each community, did not allow the use of a step-wedge or waitlist control design. Given all of these factors, we opted for cluster randomization.
Reviewer: 3
Reviewer Name: Stephen O'Lerary Institution and Country: University of Melbourne, Australia Competing Interests: None p8 li50-55: Understanding this sentence is hard work. Could it be revised, using simpler language?
We have revised this sentence for clarity (p8). p12: lie 39: "Including all types of providers", might be better as: " The inclusion of all types of providers"
The suggested edit has been added (p12). p14 li 24: Is there a precedent to justify the assumption that there might be expected to be 80% recruitment. This is very high! We have clarified that we believe a high level of recruitment is feasible because all children in the district are already participating in state-mandated school screening (p14). P14 li 31: What is the trial vulnerability to specific communities not wishing to participate? How are the investigators mitigating this risk? For instance, one possible outcome of the consultation process is that (a) key opinion leader(s) in a community advises to others that they would be best not to participate. this could influence opinion in other communities. The knock-on effects would be quite devastating.
The study is a community-driven endeavor to address childhood hearing loss across the Norton Sound region of rural, northwest Alaska. You raise an interesting and valid point that a single opinion leader in a community could influence participation in that community. We have mitigated that risk by providing multiple avenues for community participation and feedback, which are detailed in the mixed methods companion protocol. p15: li 20: Has data linkage been agreed to? this is often a critical impasse for studies across Governmental bodies.
Yes, linkage was approved. This information has been added to the protocol (p15). p15, Li31-2: How will the risk that students will forget that they have been given paper versions of the trial questions be managed? Many children, especially teenagers, simply forget that they have been given material to take home to parents! We engage with each community during travel to perform school screenings. Families have the opportunity to turn in the survey to the school before we arrive, submit it to us while we are visiting their community, or complete the survey by phone. Maintaining flexibility with multiple avenues for submission helps to mitigate this risk. p18, li 16: It would be good to specify what defines management, especially given that it will be heterogenous and may be interpreted differently by different trial staff. decisions will need to be made on some difficult questions here: is "watchful waiting" active management? the management of a child too young for myringoplasty might simply be to wait. Will that be defined as active management? Furthermore, even after successful myringoplasty a mild conductive hearing loss can persist. Will this be defined as restoring hearing or not?
We have defined active management as an audiology or ENT encounter within 3 months of the date of screening or a child wearing a hearing aid on screening day (p18). This definition was selected to encompass the heterogeneity of active management for all types of ear and hearing disorders, which includes watchful waiting.
Your point of persistent mild conductive hearing loss after myringoplasty is a good one. We recognize that even after complete treatment, sometimes hearing will not be restored to normal. Because we are evaluating the efficacy of telemedicine referral at a population level and not for management of a specific condition, we have not developed continencies or caveats for the myriad of conditions that will be discovered and treated in this trial. Our primary outcome is time to diagnosis (a proxy for time to entry to the healthcare system). The secondary outcome relevant to your question, change in hearing loss prevalence, will be measured by the WHO definition of PTA >25dB (0.5, 1, 2, 4kHz) and will not be adjusted for type of treatment. P21 li13: de-identified -strictly speaking, this is potentially reidentifiable data.
Thank you for this comment. We have clarified that we will share summary information on the mHealth screening protocol and telemedicine referral process. If a request for raw data is made, only a HIPPA compliant, de-identified dataset would be shared to protect patient privacy (p20). p22 li 6-7: One risk of successful tele-health referral is that the hospital waiting list becomes longer, meaning that there is a risk that the child will still not get an earlier diagnosis. Will waiting time on the hospital waiting list be considered as a potential co-variant?
Thank you for this comment. We discussed this possibility with our lead ENT stakeholder when initially designing the study. The Alaska telemedicine network is already high-volume (4000 ENT consults were read in 2016 alone), so the addition of ~200-250 annual referrals from the telemedicine referral arm of this study was not viewed as a concern. Because this is a population-based study where all ear and hearing problems identified during school screening are included and will require evaluation and treatment in a myriad of different ways, there is no straightforward way to measure wait time for the purposes of the overall trial. We will evaluate treatment pathways for specific diagnoses during secondary analyses that will shed light on this question. p42, li 35: How is bass of the "purposeful sampler" avoided in choosing who to interview?
Apologies, but we do not have a p42, so we are unsure exactly what this question is referencing. Perhaps "bass" was meant to be "bias" and the page was meant to be PDF page 24 (Mixed methods manuscript), Figure 1 , where "purposive sampling" is mentioned. Qualitative samples are typically smaller than those employed in quantitative methods, and may focus on outlying rather than normative cases. The most useful generalizations from qualitative studies are analytic, not "sample to
